Esperion Therapeutics (ESPR) Tops Q2 EPS by 15c

Esperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($0.46), $0.15 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $25.79 million versus the consensus estimate of $24.64 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Morgan Stanley Downgrades Stellantis NV (STLA:FP) (STLA) to Underweight
• UBS Starts F.N.B. Corporation (FNB) at Neutral